Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is a serious infection resulting in 20–50% 90-day mortality. MRSA is resistant to the most useful class of antibiotics. The limitations of vancomycin, the current standard therapy for MRSA, make treatment difficult. Although MRSA is resistant to beta-lactams, lab studies show that they enhance vancomycin’s bacterial killing when used together. CAMERA2 is an RCT comparing vancomycin alone to combination therapy (vancomycin plus flucloxacillin) for adults with MRSA blood stream infection.
The aim of the CAMERA Trial is to determine whether the addition of an anti-staphylococcal penicillin to standard therapy results in improved clinical outcomes in MRSA bacteraemia.
The trial is co-ordinated by The Menzies School of Health Research in Darwin, Australia, an independent health research institute.
This trial uses our Spinnaker software to randomise patients in 29 locations across Australia, New Zealand, Singapore and Israel. Spinnaker provides an integrated, easy to use randomisation and eCRF solution. Events such as SAE are recorded and reported as they happened. Spinnaker also provides a level of study management tools to assist the Chief Investigator and Project Manager. These included reporting on trial progress, interim reports, and management of user access to the software.
To deliver this project on time and on budget we used our agile development methodology where we use the existing code blocks within Spinnaker then iterate through a tailoring process to deliver a finely tuned product.
To hear more about how Spinnaker helps with the CAMERA Trial, read the case study or get in touch.